Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Chinese University of Hong Kong · University of Oxford · +12 more institutions
Abstract
The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.
We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy.
Citation impact
- FWCI
- 145.49
- Percentile
- 100%
- References
- 21
Authors
18- RRRury R. HolmanCorresponding
Chinese University of Hong Kong, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism
- MAM. Angelyn Bethel
Chinese University of Hong Kong, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism
- RJRobert J. Mentz
Duke University, Chinese University of Hong Kong, Clinical Research Institute, Oxford Centre for Diabetes, Endocrinology and Metabolism
- VPVivian P. Thompson
Duke University, Chinese University of Hong Kong, Clinical Research Institute, Oxford Centre for Diabetes, Endocrinology and Metabolism
- YLYuliya Lokhnygina
Duke University, Chinese University of Hong Kong, Clinical Research Institute, Oxford Centre for Diabetes, Endocrinology and Metabolism
Topics & keywords
- Medicine
- Exenatide
- Hazard ratio
- Myocardial infarction
- Placebo
- Interquartile range
- Internal medicine
- Stroke (engine)
- Good health and well-being